{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:45:04Z","timestamp":1777635904269,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00108-020-00923-9","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T12:04:10Z","timestamp":1610625850000},"page":"163-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Virushepatitis A\u2013E","Viral hepatitis A\u2013E"],"prefix":"10.1007","volume":"62","author":[{"given":"Annegrit","family":"Decker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Neumann-Haefelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"923_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway\u00a0JD, Flaxman\u00a0AD, Naghavi\u00a0M et\u00a0al (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081\u20131088. https:\/\/doi.org\/10.1016\/S0140-6736(16)30579-7","journal-title":"Lancet"},{"key":"923_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thomas","year":"2019","unstructured":"Thomas\u00a0DL (2019) Global elimination of chronic hepatitis. N\u00a0Engl J Med 380:2041\u20132050. https:\/\/doi.org\/10.1056\/NEJMra1810477","journal-title":"N Engl J Med"},{"key":"923_CR3","unstructured":"WHO (2017) Global hepatitis report 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/255016. Zugegriffen: 28.\u00a0Juli 2020"},{"key":"923_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-658-26022-4","volume-title":"Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2018","author":"Robert Koch-Institut","year":"2019","unstructured":"Robert Koch-Institut (2019) Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2018. RKI, Berlin"},{"key":"923_CR5","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1016\/j.vaccine.2010.08.037","volume":"28","author":"KH Jacobsen","year":"2010","unstructured":"Jacobsen\u00a0KH, Wiersma\u00a0ST (2010) Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 28:6653\u20136657. https:\/\/doi.org\/10.1016\/j.vaccine.2010.08.037","journal-title":"Vaccine"},{"key":"923_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0891-5520(05)70123-9","volume":"14","author":"NM Kemmer","year":"2000","unstructured":"Kemmer\u00a0NM, Miskovsky\u00a0EP (2000) Hepatitis A. Infect Dis Clin North Am 14:605\u2013615. https:\/\/doi.org\/10.1016\/S0891-5520(05)70123-9","journal-title":"Infect Dis Clin North Am"},{"key":"923_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach\u00a0S, Zeuzem\u00a0S, Manns\u00a0M et\u00a0al (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161\u2013176. https:\/\/doi.org\/10.1016\/S2468-1253(16)30181-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"923_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale\u00a0AJ, Kreuels\u00a0B, Henrion\u00a0MYR et al (2020) The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J\u00a0Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008","journal-title":"J Hepatol"},{"key":"923_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jhep.2018.02.031","volume":"69","author":"D Westh\u00f6lter","year":"2018","unstructured":"Westh\u00f6lter\u00a0D, Hiller\u00a0J, Denzer\u00a0U et al (2018) HEV-positive blood donations represent a\u00a0relevant infection risk for immunosuppressed recipients. J\u00a0Hepatol 69:36\u201342. https:\/\/doi.org\/10.1016\/j.jhep.2018.02.031","journal-title":"J Hepatol"},{"key":"923_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa0706992","volume":"358","author":"N Kamar","year":"2008","unstructured":"Kamar\u00a0N, Selves\u00a0J, Mansuy\u00a0JM et al (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N\u00a0Engl J Med 358:811\u2013817. https:\/\/doi.org\/10.1056\/NEJMoa0706992","journal-title":"N Engl J Med"},{"key":"923_CR11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","volume":"68","author":"HR Dalton","year":"2018","unstructured":"Dalton\u00a0HR, Kamar\u00a0N, Baylis\u00a0SA et\u00a0al (2018) EASL clinical practice guidelines on hepatitis E virus infection. J\u00a0Hepatol 68:1256\u20131271. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.005","journal-title":"J Hepatol"},{"key":"923_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","volume":"17","author":"K Deterding","year":"2017","unstructured":"Deterding\u00a0K, Spinner\u00a0CD, Schott\u00a0E et al (2017) Ledipasvir plus sofosbuvir fixed-dose combination for 6\u00a0weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2\u00a0study. Lancet Infect Dis 17:215\u2013222. https:\/\/doi.org\/10.1016\/S1473-3099(16)30408-X","journal-title":"Lancet Infect Dis"},{"key":"923_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.gtc.2020.01.011","volume":"49","author":"A Goel","year":"2020","unstructured":"Goel\u00a0A, Aggarwal\u00a0R (2020) Hepatitis E: epidemiology, clinical course, prevention, and treatment. Gastroenterol Clin North Am 49:315\u2013330. https:\/\/doi.org\/10.1016\/j.gtc.2020.01.011","journal-title":"Gastroenterol Clin North Am"},{"key":"923_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1055\/a-0640-3627","volume":"144","author":"H Luxenburger","year":"2019","unstructured":"Luxenburger\u00a0H, Thimme\u00a0R, Neumann-Haefelin\u00a0C (2019) Virushepatitis \u2013 wann daran denken? Dtsch Med Wochenschr 144:520\u2013527. https:\/\/doi.org\/10.1055\/a-0640-3627","journal-title":"Dtsch Med Wochenschr"},{"key":"923_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00108-017-0262-8","volume":"58","author":"R Bartenschlager","year":"2017","unstructured":"Bartenschlager\u00a0R, Cornberg\u00a0M, Pietschmann\u00a0T (2017) Ma\u00dfgeschneiderte Therapie der Virushepatitis der Gegenwart und Zukunft \u2013 Hepatitis B,C, Delta und E. Internist 58:666\u2013674. https:\/\/doi.org\/10.1007\/s00108-017-0262-8","journal-title":"Internist"},{"key":"923_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg\u00a0M, Protzer\u00a0U, Petersen\u00a0J et al (2011) Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion: AWMF-Register-Nr.: 021\/011. Z\u00a0Gastroenterol 49:871\u2013930. https:\/\/doi.org\/10.1055\/s-0031-1273462","journal-title":"Z Gastroenterol"},{"key":"923_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico\u00a0P, Agarwal\u00a0K, Berg\u00a0T et\u00a0al (2017) EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J\u00a0Hepatol 67:370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"923_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"WJ Jeng","year":"2018","unstructured":"Jeng\u00a0WJ, Chen\u00a0YC, Chien\u00a0RN et\u00a0al (2018) Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen\u2013negative chronic hepatitis B. Hepatology 68:425\u2013434. https:\/\/doi.org\/10.1002\/hep.29640","journal-title":"Hepatology"},{"key":"923_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-0043-114048","volume":"143","author":"M Cornberg","year":"2018","unstructured":"Cornberg\u00a0M (2018) Hepatitis B \u2013 Ein Ausblick auf aktualisierte Leitlinien. Dtsch Med Wochenschr 143:183\u2013188. https:\/\/doi.org\/10.1055\/s-0043-114048","journal-title":"Dtsch Med Wochenschr"},{"key":"923_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning\u00a0GC, Zoulim\u00a0F, Hou\u00a0J, Bertoletti\u00a0A (2019) Therapeutic strategies for hepatitis B virus infection: towards a\u00a0cure. Nat Rev Drug Discov 18:827\u2013844. https:\/\/doi.org\/10.1038\/s41573-019-0037-0","journal-title":"Nat Rev Drug Discov"},{"key":"923_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1055\/a-0837-2424","volume":"144","author":"T Boettler","year":"2019","unstructured":"Boettler\u00a0T, Lohmann\u00a0V, Bartenschlager\u00a0R (2019) Hepatitis C \u2013 von der individuellen Heilung zur weltweiten Elimination? Dtsch Med Wochenschr 144:535\u2013542. https:\/\/doi.org\/10.1055\/a-0837-2424","journal-title":"Dtsch Med Wochenschr"},{"key":"923_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s00108-018-0429-y","volume":"59","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem\u00a0S (2018) Chronic hepatitis\u00a0C: standard treatment and remaining challenges. Internist 59:528\u2013535. https:\/\/doi.org\/10.1007\/s00108-018-0429-y","journal-title":"Internist"},{"key":"923_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"JM Pawlotsky","year":"2018","unstructured":"Pawlotsky\u00a0JM, Negro\u00a0F, Aghemo\u00a0A et\u00a0al (2018) EASL recommendations on treatment of hepatitis C 2018. J\u00a0Hepatol 69:461\u2013511. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026","journal-title":"J Hepatol"},{"key":"923_CR24","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif\u00a0O, Jiang\u00a0ZG, Tapper\u00a0EB et al (2018) Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 154:2111\u20132121.e8. https:\/\/doi.org\/10.1053\/j.gastro.2018.03.022","journal-title":"Gastroenterology"},{"key":"923_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/a-0599-1320","volume":"56","author":"C Sarrazin","year":"2018","unstructured":"Sarrazin\u00a0C, Zimmermann\u00a0T, Berg\u00a0T et al (2018) S3-Leitlinie \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion\u201c: AWMF-Register-Nr.: 021\/012. Z\u00a0Gastroenterol 56:756\u2013838. https:\/\/doi.org\/10.1055\/a-0599-1320","journal-title":"Z Gastroenterol"},{"key":"923_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","volume":"69","author":"LS Belli","year":"2018","unstructured":"Belli\u00a0LS, Perricone\u00a0G, Adam\u00a0R et\u00a0al (2018) Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J\u00a0Hepatol 69:810\u2013817. https:\/\/doi.org\/10.1016\/j.jhep.2018.06.010","journal-title":"J Hepatol"},{"key":"923_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1053\/j.gastro.2018.07.008","volume":"155","author":"D Kim","year":"2018","unstructured":"Kim\u00a0D, Li\u00a0AA, Gadiparthi\u00a0C et al (2018) Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology 155:1154\u20131163.e3. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.008","journal-title":"Gastroenterology"},{"key":"923_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","volume":"19","author":"H Wedemeyer","year":"2019","unstructured":"Wedemeyer\u00a0H, Yurdaydin\u00a0C, Hardtke\u00a0S et al (2019) Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a\u00a0randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 19:275\u2013286. https:\/\/doi.org\/10.1016\/S1473-3099(18)30663-7","journal-title":"Lancet Infect Dis"},{"key":"923_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov\u00a0P, Alexandrov\u00a0A, Voronkova\u00a0N et\u00a0al (2016) Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a\u00a0phase Ib\/IIa study. J\u00a0Hepatol 65:490\u2013498. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016","journal-title":"J Hepatol"},{"key":"923_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.24875\/AIDSRev.19000080","volume":"21","author":"K Deterding","year":"2019","unstructured":"Deterding\u00a0K, Wedemeyer\u00a0H (2019) Beyond pegylated interferon-alpha: new treatments for hepatitis delta. AIDS Rev 21:126\u2013134. https:\/\/doi.org\/10.24875\/AIDSRev.19000080","journal-title":"AIDS Rev"},{"key":"923_CR31","unstructured":"MYR Pharmaceuticals (2020) MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX. https:\/\/www.prnewswire.com\/news-releases\/myr-pharmaceuticals-receives-conditional-marketing-authorization-by-the-european-commission-for-hepcludex-301105418.html?tc=eml_cleartime. Zugegriffen: 11. Aug. 2020"},{"key":"923_CR32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","volume":"393","author":"A Heffernan","year":"2019","unstructured":"Heffernan\u00a0A, Cooke\u00a0GS, Nayagam\u00a0S et\u00a0al (2019) Scaling up prevention and treatment towards the elimination of hepatitis C: a\u00a0global mathematical model. Lancet 393:1319\u20131329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32277-3","journal-title":"Lancet"},{"key":"923_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/ciy545","volume":"68","author":"DL Braun","year":"2019","unstructured":"Braun\u00a0DL, Hampel\u00a0B, Martin\u00a0E et al (2019) High number of potential transmitters revealed in a\u00a0population-based systematic hepatitis C Virus RNA screening among human immunodeficiency virus-infected men who have sex with men. Clin Infect Dis 68:561\u2013568. https:\/\/doi.org\/10.1093\/cid\/ciy545","journal-title":"Clin Infect Dis"},{"key":"923_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.25646\/6233.7","volume":"34","author":"Robert Koch-Institut","year":"2019","unstructured":"Robert Koch-Institut (2019) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 34:313\u2013364. https:\/\/doi.org\/10.25646\/6233.7","journal-title":"Epidemiol Bull"},{"key":"923_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1406011","volume":"372","author":"J Zhang","year":"2015","unstructured":"Zhang\u00a0J, Zhang\u00a0XF, Huang\u00a0SJ et al (2015) Long-term efficacy of a\u00a0hepatitis E vaccine. N\u00a0Engl J Med 372:914\u2013922. https:\/\/doi.org\/10.1056\/NEJMoa1406011","journal-title":"N Engl J Med"},{"key":"923_CR36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1055\/s-0034-1369902","volume":"139","author":"R Thimme","year":"2014","unstructured":"Thimme\u00a0R, Heim\u00a0M, Baumert\u00a0TF et al (2014) Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie: Teil 2 \u2013 Hepatitis-C-Virus. Dtsch Med Wochenschr 139:778\u2013782. https:\/\/doi.org\/10.1055\/s-0034-1369902","journal-title":"Dtsch Med Wochenschr"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00923-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-020-00923-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00923-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T16:12:48Z","timestamp":1612455168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-020-00923-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00923-9","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"14 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>R. Thimme<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorar: Falk Foundation e.\u202fV., Vortragst\u00e4tigkeit: Bayer Vital GmbH, med publico GmbH. \u2013\u00a0Berater: med publico GmbH, Fraunhofer-Gesellschaft, Roche, OPASCA, Topas Therapeutics GmbH, AbbVie, Advisory Boards: Gilead, Redaktion: Thieme Verlag, Falk Foundation, Co-Associate: <i>Gut<\/i>, Innovationsausschuss beim Gemeinsamen Bundesausschuss (G-BA), verschiedene Gutachtert\u00e4tigkeiten f\u00fcr Stiftungen.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: \u00e4rztlicher Direktor, Klinik f\u00fcr Innere Medizin\u00a0II, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), American Society for Clinical Investigation (ASCI), Leopoldina, American Association for the Study of Liver Diseases (AASLD), Deutsche Arbeitsgemeinschaft zum Studium der Leber (GASL), European Association for the Study of the Liver (EASL), Deutsche Gesellschaft f\u00fcr Ultraschall in der Medizin (DEGUM). <b>A.\u00a0Decker<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorar: Falk Foundation e.\u202fV., Erstattung der Reise- und \u00dcbernachtungskosten als passiver Teilnehmer: gesponserte Fortbildungen durch MSD. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Klinik f\u00fcr Innere Medizin\u00a0II, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: DGIM, DGVS, Deutsche Gesellschaft f\u00fcr Endoskopie und Bildgebende Verfahren (DGE-BV). <b>C.\u00a0Neumann-Haefelin<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorare: Falk Foundation e.\u202fV., MSD Sharp & Dohme GmbH.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Klinik f\u00fcr Innere Medizin\u00a0II, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: DGVS, EASL, AASLD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}